

# Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

NCT06909253

---

**Status** RECRUITING  
**Sponsor** AstraZeneca  
**Enrollment** 50 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Adult (aged e18 years) patients with gMG, naive to complement inhibitors, receiving ravulizumab treatment in the frames of NDP in Poland.
- Patients willing to participate in the study and signed Informed Consent Form (ICF).
- Vaccination against N. meningitidis

### Exclusion (2)

- Those who plan to participate in gMG clinical trial on/after the date of first ravulizumab infusion through NDP.
- Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

## Locations (14 total)

---

Research Site, Bydgoszcz, Poland  
Research Site, Gdansk, Poland  
Research Site, Katowice, Poland  
... and 11 more locations